Analysis Tools
hematopoietic system
|
• spleens of all transgenic mice are enlarged
• transgenic mice with leukemia have massive splenomegaly
|
|
• transgenic spleens contain greatly elevated numbers of hematopoietic cells staining for the myeloid marker myeloperoxidase
• promyelocyte-specific endogenous (mouse) Ctsg mRNA is detected by RNase protection in spleens of transgenic, but not of wild-type mice
• spleens of transgenic mice with leukemia contain early-stage myeloid cells in such large numbers they disrupt the spleen architecture
|
|
• the bone marrow of all mice expressing this transgene is crowded with immature and mature myeloid cells
|
|
• transgenic mice with leukemia may have thrombocytopenia; however, none develop bleeding diatheses and/or disseminated intravascular coagulation
|
|
• peripheral blood counts of nonleukemic transgenic mice are normal but for a slight yet significant elevation of mature myeloid cell numbers
|
|
• the interfollicular zones (red pulp) of transgenic spleens are expanded and contain greatly elevated numbers of hematopoietic cells staining for the myeloid marker myeloperoxidase
• in transgenic mice with leukemia, the foliar architecture of the spleen is disrupted by large numbers of early-stage myeloid cells
|
immune system
|
• spleens of all transgenic mice are enlarged
• transgenic mice with leukemia have massive splenomegaly
|
|
• transgenic spleens contain greatly elevated numbers of hematopoietic cells staining for the myeloid marker myeloperoxidase
• promyelocyte-specific endogenous (mouse) Ctsg mRNA is detected by RNase protection in spleens of transgenic, but not of wild-type mice
• spleens of transgenic mice with leukemia contain early-stage myeloid cells in such large numbers they disrupt the spleen architecture
|
|
• peripheral blood counts of nonleukemic transgenic mice are normal but for a slight yet significant elevation of mature myeloid cell numbers
|
|
• the interfollicular zones (red pulp) of transgenic spleens are expanded and contain greatly elevated numbers of hematopoietic cells staining for the myeloid marker myeloperoxidase
• in transgenic mice with leukemia, the foliar architecture of the spleen is disrupted by large numbers of early-stage myeloid cells
|
liver/biliary system
|
• livers of transgenic mice with leukemia become enlarged due to accumulation of immature myeloid cells
|
neoplasm
|
• approximately 30% of transgenic mice of the 6 lines expressing the transgene eventually develop severe leukemia; the earliest cases occur at 6 months and new cases continue to occur as the mice age
• myeloid cells at various stages of differentiation account for a high proportion of peripheral blood and bone marrow cells of transgenic mice with leukemia
• S1 nuclease protection assays demonstrate expression of the transgene in peripheral blood cells of leukemic mice
• culture of splenocytes from leukemic or nonleukemic transgenic mice with all-trans retinoic acid (ATRA) reduces initially high Ctsg transcript levels to levels undetectable by S1 nuclease analysys within 2 days; clumps of undifferentiated myeloid cells present in untreated splenocyte cultures involute and are invaded by macrophages following ATRA treatment
• splenocytes from transgenic mice with leukemia reproducibly transmit the leukemic phenotype to C3.Cg-Prkdcscid mice
|
growth/size/body
|
• livers of transgenic mice with leukemia become enlarged due to accumulation of immature myeloid cells
|
|
• spleens of all transgenic mice are enlarged
• transgenic mice with leukemia have massive splenomegaly
|
|
• transgenic spleens contain greatly elevated numbers of hematopoietic cells staining for the myeloid marker myeloperoxidase
• promyelocyte-specific endogenous (mouse) Ctsg mRNA is detected by RNase protection in spleens of transgenic, but not of wild-type mice
• spleens of transgenic mice with leukemia contain early-stage myeloid cells in such large numbers they disrupt the spleen architecture
|
